Table 1.
Clinical characteristics of SARS-CoV-2 and influenza coinfection, COVID-19 epidemic.
| References | Sex | Age | Comorbidities | Coinfection | Oseltamivir | Antivirals | Glucorticoids | ARDS | ICU | NIV | IMV | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azekawa et al. (2020) | F | 78 | Dyslipidemia, hypothyroidism | Influenza A | Yes | No | No | No | No | No | No | Survived |
| Blasco et al. (2020) | NA | NA | NA | Influenza A and RSV | NA | NA | NA | NA | NA | NA | NA | NA |
| Cuadrado-Payán et al. (2020) | M | 53 | ERSD | Influenza A | Yes | Yes | NA | Yes | Yes | No | Yes | Survived |
| M | 78 | T2DM | Influenza A | Yes | Yes | NA | Yes | Yes | No | Yes | Survived | |
| M | 56 | T2DM | Influenza A and B | No | No | NA | No | No | No | No | Survived | |
| F | 81 | ERSD | Influenza B | Yes | Yes | NA | Yes | Yes | No | Yes | Survived | |
| de Souza Luna et al. (2020) | NA | 36 | NA | Influenza B | NA | NA | NA | NA | NA | NA | NA | NA |
| Ding et al. (2020) | F | 47 | None | Influenza A | Yes | Yes | Yes | No | No | No | No | Survived |
| M | 50 | Hypertension, cancer | Influenza A | Yes | Yes | Yes | Yes | No | Yes | No | Survived | |
| F | 66 | Hypertension, CVD, HBV | Influenza B | Yes | Yes | No | No | No | No | No | Survived | |
| M | 39 | HBV | Influenza B | Yes | Yes | Yes | No | No | No | No | Survived | |
| F | 49 | None | Influenza A | Yes | Yes | No | No | No | No | No | Survived | |
| Garazzino et al. (2020) | NA | <17 | NA | Influenza A | NA | NA | NA | NA | NA | NA | NA | NA |
| Hashemi et al. (2020) | F | 78 | NA | Influenza A | Yes | Yes | NA | Yes | NA | NA | NA | Dead |
| M | 75 | NA | Influenza A | Yes | Yes | NA | Yes | NA | NA | NA | Dead | |
| Khodamoradi et al. (2020) | F | 74 | Hypertension, CVD | Influenza A | Yes | Yes | No | No | No | No | No | Survived |
| M | 40 | None | Influenza A | Yes | Yes | No | No | No | No | No | Survived | |
| M | 64 | None | Influenza A | Yes | Yes | No | No | No | No | No | Survived | |
| M | 50 | None | Influenza A | Yes | Yes | No | No | No | No | No | Survived | |
| Kim et al. (2020) | NA | NA | NA | Influenza A | NA | NA | NA | NA | NA | NA | NA | NA |
| Konala et al. (2020b) | M | 57 | Hypertension, T2DM, CVD, AICD | Influenza A | Yes | Yes | No | No | No | No | No | Survived |
| F | 35 | Sickle cell trait | Influenza A | Yes | Yes | No | No | No | No | No | Survived | |
| F | 68 | T2DM, hypertension, GERD | Influenza B | Yes | Yes | NA | Yes | Yes | No | Yes | Dead | |
| Konala et al. (2020a) | F | 66 | T2DM, CVD, hypertension, CKD | Influenza A | Yes | Yes | NA | Yes | Yes | No | Yes | Survived |
| Nowak et al. (2020) | NA | NA | NA | Influenza A | NA | NA | NA | NA | NA | NA | NA | NA |
| Pongpirul et al. (2020) | M | 61 | None | Influenza A | Yes | No | No | No | No | No | No | Survived |
| Richardson et al. (2020) | NA | NA | NA | Influenza A | NA | NA | NA | NA | NA | NA | NA | NA |
| Wehl et al. (2020) | NA | 4 months | None | Influenza A | Yes | No | No | No | No | No | No | Survived |
| Wu et al. (2020b) | NA | <17 | NA | MP, Influenza A&B, RSV | NA | NA | NA | NA | NA | NA | NA | NA |
| Wu et al. (2020c) | M | 69 | None | Influenza A | Yes | NA | NA | Yes | Yes | No | Yes | Survived |
| Zhu et al. (2020) | NA | NA | NA | 2 pts Influenza A | NA | NA | NA | NA | NA | NA | NA | NA |
| 5 pts Influenza B |
SARS-CoV-2: severe acute respiratory syndrome coronavirus-2, COVID-19: coronavirus disease-19, CVD: cardiovascular disease, HBV: hepatitis B virus, NA: not available, ARDS; Acute Respiratory Distress Syndrome, ICU: Intensive Care Unit, NIV: non-invasive ventilation, IMV: invasive mechanical ventilation, T2DM: type 2 diabetes mellitus. AICD: automatic implantable cardioverter defibrillator. RSV: Respiratory syncytial virus. MP: Mycoplasma pneumonia. ESRD: end-stage kidney disease. CKD: chronic kidney disease. GERD: gastroesophageal reflux disease.